Published in Hepatitis Weekly, June 10th, 2002
This US$36.96 million acquisition will expand its existing product pipeline to include a new immune-regulating platform drug, known as WF10, currently in development for the treatment of AIDS and hepatitis C.
Under the terms of the purchase agreement, $500,000 in cash is payable on closing (scheduled for May 31, 2002) and a further $500,000 cash payment is due in November 2002. Additional payments of $4.0 million in November 2002, $4.24 million in November 2003 and $9.24 million in each of November 2004, 2005 and 2006, may be made in any...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.